Clinical observation of palonosetron, dexamethasone and droperidol in preventing nausea and vomiting after gynecological laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062733

Enrollment

Unknown

Registered

2022-08-16

Start date

2022-08-15

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PONV

Interventions

group PDD: Palonosetron 0.075mg + dexamethasone 4mg + droperidol 0.625mg, intravenous injection before induction

groupPD:Palonosetron 0.075mg + dexamethasone 4mg , intravenous injection before induction

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing gynecological laparoscopic surgery under elective general anesthesia; 2. aged 18 ~ 60 years; 3. ASA physical condition grade I or II.

Exclusion criteria

Exclusion criteria: Patients with pregnancy or lactation, mental or neurological diseases, preoperative application of antiemetics or emetics, previous diagnosis of long QT syndrome, obvious arrhythmia, history of allergy to palonosetron, droperidol and dexamethasone, and history of opioid abuse.

Design outcomes

Primary

Measure	Time frame
Incidence of PONV within 6 hours after operation;Incidence of PONV within 6-24 hours after operation;	—

Secondary

Measure	Time frame
Incidence and degree of nausea within 6 hours after operation;Intraoperative opioid dosage and sevoflurane dosage;Adverse reactions within 24 hours after operation;	—

Countries

China

Contacts

Public ContactYuanxu Jiang

Shenzhen people's Hospital

13613051840@163.com+86 13613051840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026